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Summary 
Cerebral deposition of amyloid p protein (AI~) is an 
early and critical feature of AIzheimer's disease. Here 
we analyze the substrate requirements of proteases 
("l~-secretases'3 that cleave the I~-amyloid precursor 
protein (I~APP) at the N-terminus of AI~ (Asp-597 of 
I~APP6~s) in intact human cells. The cleavage requires 
a membrane-bound substrate but tolerates shifts in 
the distance of the hydrolyzed bond from the mem- 
brane. The major protease has a minimum recognition 
region of Val-594 to Ala-598; most substitutions in this 
sequence strongly decrease or eliminate AI~ produc- 
tion. Only the Swedish familial Alzheimer's disease 
mutation (K595N/M596L) strongly increases AI~ pro- 
duction. Moreover, in this mutant but not in the wild 
type, the entire cytoplasmic tail with its reinternaliza- 
tion signals can be deleted without affecting AI~ N-ter- 
minal cleavage, consistent with the concept that cleav- 
age of this mutant occurs in a different cellular 
compartment than that of wild-type molecules. Our re- 
sults have important implications for current intensive 
approaches to develop assays for and identify en- 
zymes with I~-secretase activity. 
Introduction 
Alzheimer's disease is characterized by the progressive 
formation in the brain of insoluble amyloid plaques and 
vascular deposits consisting of the 4 kDa amyloid 13 pep- 
tide (AJ~; Glenner and Wong, 1984; Masters et al., 1985). 
AI3 is proteolytically derived from a large integral mem- 
brane protein, the l~-amyloid precursor protein (J3APP). 
Four Al3-containing isoforms of 13APP, comprising 695, 
714, 751, or 770 amino acids, have been described (Kang 
et al., 1987; Ponte et al., 1988; Ta.nzi et al., 1988; Kitaguchi 
et al., 1988; Golde et al., 1990). The two longer isoforms 
contain a serine protease inhibitory domain of the Kunitz 
type. After maturation within the endoplasmic reticulum 
and Golgi, I3APP undergoes a constitutive "a-secretory" 
proteolytic leavage to release the large soluble N-terminal 
ectodomain (APP,) and create a 10 kDa C-terminal frag- 
ment that remains membrane bound (Figure 1) (Weide- 
mann et al., 1989; Esch et al., 1990; Oltersdorf et al., 1990; 
Sisodia et al., 1990). in this pathway, 13APP is cleaved 
within the AI3 domain primarily between residues Lys-16 
and Leu-17, precluding formation of intact AI3 (Esch et 
al., 1990). Recently, it has been shown that alternative 
cleavage sites within the AI3 region can be used in different 
cells, suggesting that a-secretase cleavage is likely to in- 
volve a diverse set of proteases (Zhong et al., 1994). 
The enzyme(s) responsible for this e-secretory cleavage 
has not yet been isolated, but indirect evidence suggests 
that the major form of a-secretase is a membrane-bound 
enzyme that cleaves ~APP on the plasma membrane (Si- 
sodia, 1992). It has been suggested that the principal de- 
terminants of cleavage are an a-helical conformation 
around the cleavage site and the distance of the hy- 
drolyzed peptide bond from the membrane, not the pri- 
mary structure in this region (Sisodia, 1992). AI3 must be 
generated by an alternative pathway that involves at least 
two proteolytic cuts, one at the N-terminus by an en- 
zyme(s) designated 13-secretase and one at the C-terminus 
by y-secretase (Figure 1). Thus, a potential therapeutic 
strategy for decreasing A~ deposition in AIzheimer's dis- 
ease involves inhibition of specific enzymes performing 
one or both of these cuts. 
A~ production and release are normal physiological 
events. The 4 kDa peptides precipitable by a variety of 
A~-specific antibodies are normally present in the media of 
]3APP-expressing cultured cells and in human and rodent 
cerebrospinal fluid. Most of these 4 kDa peptides secreted 
from human kidney 293 cells, human M17 neuroblastoma 
cells, and human fetal mixed brain cultures indeed start 
at Asp-1 (Haass et al., 1992b; Shoji et al., 1992; Seubert 
et al., 1992; Busciglio et al., 1993) and contain approxi- 
mately 40 amino acids. Interestingly, the amount of AI3 
released into conditioned media is markedly increased by 
a double missense mutation (K595N/M596L; Figu re 1) that 
occurs in a Swedish Alzheimer's disease family (Mullan 
et al., 1992), as seen both in transfected cell lines (Citron 
et al., 1992; Cai et al., 1993) and in primary skin fibroblasts 
from patients carrying the mutation (Citron et al., 1994). 
In addition to AJ~, a 3 kDa peptide (p3) starting at Leu-17 
is constitutively secreted. This peptide appears to be de- 
rived by "y-secretase cleavage of the 10 kDa C-terminal 
fragment of J3APP following secretion of APPs (Haass et 
al., 1993). p3 has recently been detected in diffuse plaques 
in Alzheimer brain tissue (Gowing et al., 1994). 
The precise intracellular site(s) of AI3 generation and the 
proteases involved in its production are poorly understood. 
However, recent radiosequencing studies have shown 
that 13-secretase cleavage occurs at slightly different posi- 
tions in different cell types. In 293 cells, approximately 
80% of A~ produced from wild-type 13APP molecules starts 
at Asp-l, with the rest beginning at Val(-3) and lie(-6) 
(Haass et al., 1992b); however, in primary skin fibroblasts, 
wild-type ~APP is metabolized to the Asp-1 form of AJ3 only 
(Citron et al., 1994), and in Madin-Darby canine kidney 
cells, primarily to a form starting at Arg-5 (Haass et al., 
1994). These results suggest that different cell-specific 
proteases are capable of generating the N-terminus of AJ3. 
In this study, the substrate requirements of the prote- 
ases (~-secretases) that liberate the N-terminus of AJ3 in 
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Figure 1. I3APP Structure and Processing 
The schematic shows I3APP695 with the consensus N-linked glycosyla- 
tion sites (CHO) and the restriction sites Accl (A), Xhol (X), and Bglll 
(B). The part of the I3APP molecule removed by the XB deletion is 
indicated. N, N-terminus; C, C-terminus; vertical bars, plasma mem- 
brane; black box, AI3. Solid horizontal lines represent the regions 
against which antibodies B5, C7, 1963, and R1280 were produced. 
The amino acid sequence of the A,B region of J3APP is expanded. The 
position of the Swedish (sw) FAD mutation is indicated. The sites of 
the ~-, J3-, and 7-secretase cleavages are marked by arrows. The exact 
site(s) of 7-secretase cleavage is un known, but the majority of AI3 mole- 
cules in Alzheimer brain tissue terminate at Val-40 or Ala-42 (Mori et 
al., 1992; Roher et al., 1993). The amino acids shown in bold type at 
the lower left were mutated in this study to the amino acids indicated 
in plain type; A signifies a deletion. 
293 cells and in SK-N-SH human neuroblastoma cells 
were analyzed. We show that these proteases depend on 
a membrane-bound I3APP substrate but tolerate changes 
in the distance of the cleaved peptide bond from the mem- 
brane. We define a minimal recognition sequence, docu- 
ment that the major Asp-1 cleaving enzyme is highly se- 
quence specific, and show that the 13-secretase cleavage 
occurs prior to the 7-secretase cleavage. Further, we show 
that deletion of the entire cytoplasmic tail of I3APP strongly 
influences the N-terminal cleavage pattern of wild-type but 
not of Swedish mutant I~APP, consistent with the idea that 
the N-terminal cleavage of AJ3 in these two ISAPP forms 
occurs in two different intracellular compartments. Finally, 
we discuss the implications of our results for current inten- 
sive efforts to develop an assay for a J3-secretase enzyme 
in human brain and to confirm its identity. 
Results 
Ap Production Does Not Require the N-Terminal 
Portion of pAPP 
To define a minimal region of [3APP that is obligatory for 
AI3 N-terminal cleavage in intact human cells, two J3APP695 
in-frame deletion constructs, in which the 859 bp fragment 
from Xhol to Bglll (Figure 1) is replaced by a 16 bp synthetic 
piece of DNA, were analyzed, in these constructs, amino 
acids 309-589, including the two N-glycosylation sites at 
467-469 and 496-498 (Kang et al., 1987), are deleted. 
Introduction of this deletion into a plasmid carrying the 
wild-type I3APP695 cDNA created plasmid XB, while intro- 
duction into a plasmid carrying the 13APP895 sequence with 
the Swedish double missense mutation (Citron et al., 1992) 
(Figure 1) created plasmid XBsw. Upon transfection, both 
constructs resulted in the production of A13, p3, and APPs, 
the latter being about 30 kDa smaller than the respective 
wild-type protein as a consequence of the deletion (Figure 
2A). As with full.length I]APP constructs, the Swedish mu- 
tation leads to a strong increase in the amount of AI5 (Fig- 
ure 2A). This experiment demonstrates that amino acids 
309-589 are not specifically required for the 13- and 7-se- 
cretory cleavages that generate AI3 in intact cells and are 
not involved in the increase in A13 production observed in 
the Swedish mutation. Another internal deletion construct, 
13APP6~JAX, in which amino acids 78-305, including the 
ectodomain phosphorylation site(s), were deleted (Hung 
and Selkoe, 1994) also still allowed AI3 production (Hung 
and Selkoe, unpublished ata), indicating that almost the 
entire I3APP ectodomain was dispensable with respect to 
AI3 production. 
Proteolytic Generation of the Ap N-Terminus 
Tolerates Changes of Distance to the Membrane 
It has been postulated that c~-secretase cleaves I3APP at 
a fixed distance from the membrane (Sisodia, 1992). To 
address whether the same is true for the AI~ N-terminal 
cleavage, we engineered constructs with amino acid dele- 
tions between the AI3 cleavage site and the stretch of AI3 
amino acids from 18 to 23, near the transmembrane do- 
main that is required for ct-secretase cleavage (Sisodia, 
1992). Two deletion constructs were analyzed: in &5-9 
the amino acids RHDSG of AJ3 (601-605 of IBAPPs~5) are 
deleted, and in A9-12 the amino acids GYEV (605-608) 
are deleted. Both constructs still led to the production of 
A13 and p3 peptides, as well as an APPs molecule that 
is poorly detectable by the R1280 immunoprecipitating 
antibody, owing to the deletion (Figure 2B). This finding 
demonstrates th at amino acids 5-12 of A13 are dispensable 
for protease recognition of the N-terminal cleavage site. 
Together with the results of the XB deletion (Figure 2A), 
it appears that the recognition sequence for 13-secretase 
is limited to a maximum of 11 amino acids (positions 590- 
600) immediately surrounding the cleavage site. However, 
we cannot exclude the possibility that residues C-terminal 
to amino acid 608 might also assist in proper recognition. 
An analogous insertion construct in which the amino acids 
IGFEV were inserted after the 7th amino acid of AI5 (posi- 
tion 603) led to a strong decrease in both AJ] and p3, sug- 
gesting that this insertion had disrupted the overall struc- 
ture of the molecule and thereby inhibited both ct- and 
J3-secretase cleavages (data not shown). Relative to wild- 
type I3APP, the AI~ bands derived from both deletion con- 
structs displayed decreased mobility (Figure 2B). This re- 
sult suggests that the predominant Met-Asp cleavage site 
was maintained, independently of its membrane distance. 
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Figure 2. Antibody R1280 Immunoprecipita- 
tJons of Conditioned Media from Metabolically 
Labeled Kidney 293 Cells Transiently Trans- 
fected with the Indicated Plasmids 
(A) XhoI-Bglll deletion constructs either with- 
out (XB) or with (XBsw) the Swedish double 
mutation. 0, untransfected; wt, transfected with 
wild-type ~APPes. APPs marks the region of 
the gel in which conventional soluble forms of 
6APP migrate. APPs* marks the form of APPs 
that is shortened by -30 kDa owing to the XB 
deletion. APP,* is stronger in XBsw than in XB, 
presumably because ofhigher transfection effi- 
ciency. 
(8) A~ internal deletion constructs. In A5-9, AI3 
and p3 run as distinct but very closely spaced 
bands. Radiosequencing of the upper band 
confirms that it has A~ sequence (see Figure 
3). Owing to the deletion of amino acids 9-12 
and 5-9 of A~, the C-terminus of APP, is much less well recognized by R1280. The - 200 kDa proteins detected inall immunoprecipitations and 
the -70 kDa protein in (8) are nonspecific proteins that are unrelated to ~APP (Haass et al., 1992b). 
Radiosequencing of A~ from A5-9 and A9-12 transfec- 
tants demonstrated that this is indeed the case (Figures 
3A and 3C). For Al~ from both A5-9 and A9-12, major 
peaks of 3H-phenylalanine were obtained at positions con- 
sistent with an AI~ start at Asp-1 (peak of radioactivity at 
cycle 4) and the deletion of 5 or 4 amino acids, respec- 
tively, between Phe-4 and Phe-19/20 (double peaks of ra- 
dioactivity at cycles 14/15 or 15/16, respectively). As ex- 
pected, p3 is not influenced by the deletions, and therefore 
both constructs show a p3 radiosequencing pattern very 
similar to the one previously established for wild-type 
I3APP (Haass et al., 1992b), with most of p3 starting at 
Leu-17 (Figures 3B and 3D). In summary, these data 
strongly suggest that the N-terminal cleavage generating 
AI3 can tolerate a decrease of distance of the peptide bond 
from the membrane. 
Membrane Assoc ia t ion  o f  pAPP  Is Requ i red  for  
[~-Secretase C leavage 
Next, we asked whether 13APP must be membrane bound 
for AJ3 production to occur. To address this question, five 
constructs were designed (Figure 4A), transiently 
transfected into 293 ceils, and checked for AI~ production 
(Figure 4B). The wild-type J3APP695 construct shows the 
expected bands of APPs, A~, and p3 (Figure 4B). The con- 
struct STOP51 contains a stop codon at position 648, after 
the 51st amino acid from the A[3 start site (Figure 4A), 
thus including virtually the entire ~APP transmembrane 
domain. This construct produces AJ3 and p3 comparably 
to the wild type (Figure 4B). However, products in the size 
range of APPs are markedly increased (see below). The 
construct STOP40 contains a stop codon at position 637, 
after the 40th amino acid from the AJ3 start (Figure 4A). 
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Figure 3. Radiosequencing of Al3 and p3 Pep- 
tides Secreted by 293 Cells Transfected with 
the A5-9 and A9-12 Mutations 
The 3H-phenylalanine radioactivity obtained t 
each cycle of the Edman chemistry is graphed 
for the 4 kDa (A and C) and 3 kDa (B and D) 
bands. The sequences above (A) and (C) are 
correct for the A5-9 and A9-12 molecules, re- 
spectively, i.e., they lack the deleted amino 
acids. The radiolabeled phenylalanines are in- 
dicated by bold letters (F) in each peptide se- 
quence. 
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Figure 4. Membrane Insertion of 13APP Is Re- 
quired to Generate A[~ 
(A) 13APP schematic showing the C-termini of 
STOP51 and STOP40 constructs and the NL 
substitution i  the constructs STOP51sw and 
STOP40sw. The amino acids of the transmem- 
brane domain are indicated in bold letters. 
(B) Antibody R1280 immunoprecipitations f 
conditioned media from metabolically labeled 
293 cells transiently transfected with the indi- 
cated plasmids. 
(C) Antibody 1280 (AI31~) and antibody 1963 
(AI321-37) immunoprecipitations of c nditioned 
media from metabolically abeled 293 cells 
transfected with the indicated plasmids. 
(D) Antibody B5 (to the midregion epitope 
[~APP~-592) immunoprecipitations of total ly- 
sates of the cells used in(C). The principal en- 
dogenously expressed I~APP751 precursor is in- 
dicated. 
(E) Western blot of carbonate-extracted mem- 
brane preparations from kidney cells transfected 
with the indicated plasmids, using antibody B5. 
The two endogenous I~APPTs1 bands are indi- 
cated. The I~APP~5 bands of the wild-type 
transfectant are marked (x). The lower molec- 
ular weight I~APP bands of the truncated 
STOP51sw construct are also marked (dots). 
This gel was run longer than (D) and therefore 
shows a clear separation of the N'- and the 
N'+O' glycosylated forms. 
Thus, the resulting I~APP molecule terminates at the major 
cleavage position of 7-secretase (Figure 1) and would only 
need to undergo N-terminal cleavage to generate AIS. This 
construct also produces very high amounts of material in 
the APPs size range, but secretes neither AI3 nor p3 (Figure 
4B). Similar results were obtained with the constructs 
STOP51sw and STOP40sw, which contain the Swedish 
mutation in addition to the STOP51 or STOP40 deletion, 
respectively (Figure 4B). 
The fact that the constructs STOP51 and STOP51sw 
secrete AI3 while STOP40 and STOP40sw do not strongly 
suggests that only membrane-bound 13APP can function 
as a substrate for the AI3 N-terminal protease. Both trunca- 
tion constructs lack the ~APP cytoplasmic domain, thus 
excluding the possibility that loss of this region alone 
causes the complete lack of A~ generation in STOP40 and 
STOP40sw. The only difference between the constructs 
is the length of the transmembrane region they contain: 
STOP40 and STOP40sw contain only 12 amino acids of 
the predicted 24 amino acid transmembrane domain 
(Kang et al., 1987), whereas STOP51 and STOP51 sw con- 
tain 23. It is therefore likely that the 15APP of STOP51 and 
STOP51sw occurs in considerable part as a membrane- 
bound molecule, whereas ~APP of STOP40 and STOP40sw 
does not. To test this prediction, we prepared a set of five 
dishes each from 293 cells that were either untransfected 
or transfected with 13APP895, STOP51sw, or STOP40sw 
constructs. Two dishes from each set were metabolically 
labeled. The conditioned media of these two dishes were 
pooled, and one-half was immunoprecipitated with R1280, 
which is directed against A~l_4o (Figure 4C). This precipita- 
tion showed again that AI3 and p3 are secreted at levels 
clearly above the endogenous background by wild type- 
and STOP51sw-transfected cells but not by STOP40sw- 
transfected cells. The untransfected cells showed very 
little material in the APPs size range, the wild type-trans- 
fected cells show some APPs, and both the STOP51sw- and 
STOP40sw-transfected cells have strong bands of similar 
intensity in that size range (Figure 4C). The second half 
of the conditioned media was immunoprecipitated with 
1963, an antibody to AI3 residues 21-37 beyond the 
a-secretase site that recognizes AI3 and p3 but cannot 
precipitate APPs ending at the ~-secretase site (Figure 1). 
The AI3 and p3 precipitations from the various transfec- 
tants using antibody 1963 are similar to those obtained 
with R1280, with the p3 band being slightly more pro- 
nounced relative to the A~ band (Figure 4C). However, a 
clear difference in immunoprecipitated material in the 
APP, range is obtained with 1963. No material above back- 
ground is precipitated by 1963 from wild type-transfected 
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cells, indicating that they de not release significant 
amounts of uncleaved I3APP from the membrane, as ex- 
pected. In contrast, the STOP51sw-transfected cells 
clearly show some, and the STOP40sw-transfected cells 
show much more uncleaved 13APP that has been released 
intact from the membrane, and can thus be precipitated 
from the medium with 1963. The STOP40sw construct 
releases much higher amounts of uncleaved precursor, 
but produces neither A~ nor p3; the latter, as an endpro- 
duct of the a-secretory pathway (Haass et al., 1993), is 
predicted to arise solely from membrane-associated I3APP 
(Sisodia, 1992). 
If these differences in AI~ (and p3) secretion from the 
STOP51sw and STOP40sw molecules are indeed due to 
their different levels of retention in cell membranes, one 
would expect to find full-length $TOP51sw and STOP40sw 
molecules in comparable amounts in total cell lysates, but 
only STOP51sw molecules in isolated membrane prepara- 
tions. Figure 4D shows total cell lysates from the two meta- 
bolically labeled dishes immunoprecipitated with the 
13APP midregion antibody, B5. All transfectants how the 
faint endogenous ~APPTsl species. In addition, the wild- 
type transfectant has a major full-length band representing 
13APP695 that migrates at a slightly lower molecular weight, 
as expected. The I3APP from the STOP51 deletion con- 
struct is 48 amino acids shorter than the wild-type mole- 
cule, and that from the STOP40 deletion construct is 59 
amino acids shorter; bands of accordingly lower molecular 
weight were indeed detected in these extracts. This result 
indicates that all constructs produce 13APP molecules of 
the expected size in detectable amounts. 
The remaining three dishes of each transfectant were 
used to prepare isolated carbonate-extracted membranes 
(see Experimental Procedures), which were then electro- 
phoresed on SDS gels and immunoblotted with antibody 
B5 (Figure 4E). In all cases, the H'- and N'+O'glycosylated 
forms of the endogenous I3APP751 were detected. In the 
I~APP695 wild-type transfectant, the N'+O'-glycosylated 
band of 13APP (marked by the upper "x" in Figure 4E) comi- 
grates with the N-glycosylated form of the endogenous 
13APPT~. In addition, the N-glycosylated form of the trans- 
fected I~APP69s migrating at a slightly lower molecular 
weight (marked by the lower "x") is clearly detectable. Two 
bands of lower molecular weight representing the N'- and 
N'+O'-glycosylated forms of the truncated STOP51sw mol- 
ecule (marked by dots in Figure 4E) were detected in the 
membranes of STOP51sw cells. In contrast, only ex- 
tremely faint bands, besides the endogenous 13APP751 
background proteins, were detected in the STOP40sw de- 
letion transfected cells. Together, Figures 4C-4E demon- 
strate that STOP40sw and STOP51sw are expressed and 
detectable in cell lysates. However, only STOP51sw is 
membrane inserted, and only STOP51sw undergoes the 
J3-secretase cleavage necessary for AI3 production. 
Differential Substrate Requirements for 
l~-Secretase Cleavage of Wild-Type and 
Swedish J]APP69s 
The data presented in Figure 4 seem to suggest that the 
whole 13APP C-terminus downstream of amino acid 648 
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Figure 5. Radiosequencing of Peptides Secreted by Cells Transfected 
with the STOP51 or STOP51sw Constructs 
The 3H-phenylalanine-dedved ra ioactivity obtained at each cycle of 
the Edman chemistry is graphed. 
(A) Production of the 4 kDa peptide with STOP51. The upper line at 
the top of the graph shows the sequence of the predominant species 
starting at Arg-5, and the lower line shows the sequence of A~ starting 
at Asp-l. 
(B) Production of the 4 kDa peptide with STOP51sw. The sequence 
of the regular Asp-1 species is indicated. 
(the endpoint of the STOP51 deletion) is dispensable for 
the production of A~. However, it has been shown that a 
deletion of the C-terminus of wild-type I3APP695 down- 
stream from amino acid 653 (AC), including the reinternali- 
zation motif NPTY, decreases the amount of Al3 produced 
in 293 cells (Haass et al., 1993), and that deletion of the 
reinternalization sequence YENPTY alone has the same 
effect in CHO cells (Koo and Squazzo, 1994). Further- 
more, whereas the AC mutation lowers the amount of A~ 
starting at Asp-l, radiosequencing demonstrates that it 
significantly increases the amounts of Al~-related peptides 
starting at Val(-3) (radioactive Phe at cycles 7, 22, and 23) 
and Arg-5 (radioactive Phe at cycles 15 and 16) relative 
to the amount of the Asp-1 A~ form in the same cells (Haass 
et al., 1993). Radiosequencing of AI~ from STOP51- 
transfected 293 cells confirmed this observation (Figure 
5A). Peptides starting at Arg-5 (radioactive Phe at cycles 
15 and 16) become the predominant A~ species. Surpris- 
ingly, this cytoplasmic deletion effect is not observed in 
AI~ from STOP51sw-transfected 293 cells (Figure 5B). In- 
stead, a homogenous "Asp-1 only" N-terminal cleavage 
pattern is obtained. This pattern is typical for the effects 
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Figure 6. Immunoprecipitations of Condi- 
tioned Media nd Cell Extracts from Metaboli- 
cally Labeled Cells Transiently Transfected 
with the Indicated Plasmids 
(A) R1280 immunoprecipitation of conditioned 
media from 293 transfectants. 
(B) B5 immunoprecipitation of APPs from condi- 
tioned media of 293 transfectants. 
(C) C7 immunoprecipitation of C-terminal 
~APP fragments from cell extracts of 293 
transfectants. 
(D) R1280 immunoprecipitation of conditioned 
media from SK-N-SH neuroblastoma transfec- 
tants. 
(E) B5 irnmunoprecipitation of APPs of condi- 
tioned media from SK-N-SH neuroblastoma 
cell transfectants. The APP, band resulting 
from transfection with these ~APP695 wild-type 
or mutant constructs is marked. The band im- 
mediately above it is the endogenous APP,. 
(F) C7 immunoprecipitation of C-terminal ~APP 
fragments from cell extracts of SK-N-SH neuro- 
blastoma cell transfectants. 
(G) Radiosequencing ofthe 12 kDa band from 
extracts of SK-N-SH neuroblastoma cells 
transfected with Swedish mutant .BAPP89~ and 
precipitated with antibody C7. The 3H-phe- 
nylalanine-derived radioactivity obtained at 
each cycle of the Edman chemistry isgraphed. 
For the M596V mutation, the amounts of the 10 
kDa fragment and p3 seem slightly increased in 
293 ceils (C) and strongly increased in SK-N- 
SH cells (F), probably owing to a compensatory 
increase in c~-secretase cleavage when ~-se- 
cretase cleavage is inhibited. 
of the Swedish mutation in full-length I3APP molecules and 
different from the heterogenous A~ N-terminal cleavages 
of wild-type [3AP P (Citron et al., 1994). Thus, whereas dele- 
tion of the entire cytoplasmic domain (or the YENPTY rein- 
ternalization signal alone) has a clear influence on [3-secre- 
tase cleavage of wild-type I3APP, it has little or no effect 
on 13-secretase cleavage of Swedish I3APP, consistent with 
the hypothesis that, for the latter molecule, [3-secretase 
cleavage principally occurs before reinternalization f the 
precursor. 
The N-Terminal Cleavage of Ap Is Highly 
Sequence Specific 
Previous experiments with transient and stable transfec- 
tions of plasmids carrying the Swedish mutation suggest 
that amino acid substitutions at or near the N-terminal 
cleavage site can have profound effects on the amount 
of AI3 being produced in several types of cells (Citron et 
al., 1992; Cai et al., 1993). We therefore analyzed the 
effects of other amino acid substitutions in the region from 
Val(-3) (residue 594 of 13APP895) to Ala-2 (residue 598) in 
transient ransfections. The substitution constructs are ab- 
breviated with the letter of the original amino acid, its posi- 
tion number, and the letter of the substituted amino acid; 
amino acid deletions are indicated by A. As an example 
of this set of experiments, Figure 6 shows all the I3APP 
derivatives obtained from the mutants M596V and D597A 
in both 293 cells and SK-N-SH human neuroblastoma 
cells. Conditioned media of the transfected cells were pre- 
cipitated with the APPs-reactive antibody B5, and all three 
constructs yielded APPs proteins of the same size and 
in comparable amounts, whether expressed in 293 cells 
(Figure 6B) or SK-N-SH neuroblastoma cells (Figure 6E). 
However, precipitation of the conditioned media with the 
AJ3-specific antibody R1280 revealed striking differences 
among the constructs: while all three transfectants pro- 
duced p3, which started at Leu-17 (data not shown) and 
is not observed in untransfected SK-N-SH cells, M596V 
produced no AI3 (Figures 6A and 6D). Likewise, D597A 
did not produce the 4 kDa AI3 species, but instead a - 3.8 
kDa peptide (Figures 6A and 6D) that started at Phe-4 
(radiosequencing data not shown). These results were ob- 
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A 
V594 K595 
Mr(K)  wt  t~ W N E 
14- -  
6 -  . . . . .  : .~....A~l 
3 -- - , ,~-  p3 
1.0 .28 .29 .64 .44 
B 
M596 
Mr(K)  wt  L A Y V A K E I F 
6- -  
3 - -  
1.0 1.53 .24 1.24 .31 .22 .18 .18 .06 .82 
~-- -  A8  
--~---p3 
Figure 7. Antibody R1280 Immunoprecipita- 
tions of Conditioned Media from Metabolically 
Labeled 293 Cells Transiently Transfected with 
the Indicated Ptasmids 
(A) Mutations at V594 and K595. (B) Mutations 
at M596. (C) Mutations at D597. The amount 
of AI~ in D597K is overestimated because a 
slightly smaller band is not clearly separable 
for the quantitation. (D) Mutations at A598. An 
untransfected control just expressing the en- 
dogenous I~APPTsl is also shown (lane 0). For 
each panel, the ratio of Af~ detected in condi- 
tioned medium to full-length ~APP detected in 
the cell lysate of each transfectant was deter- 
mined by phosphorimaging and normalized to 
the wild-type ratio, wNch was set at 1.0. The 
ratios are shown below each panel. The ratios 
in (C), especially for D597K, may be overesti- 
mated, since shortened AI3 fragments overlap 
the 4 kDa range that was quantitated. 
C D 
D597 A598 
Mr (K  ) wt  K G A I N E Mr (K  ) 0 wt  A E K 
14 -- 14 -- 
6-  ..~..- AB 6 -  
3 " . . . .  -,91-- p3 3 - ...... 
1.0 .69 .17 .04 .13 .21 .63 0 1.0 .26 .28 29 
-~- -  Ag 
"~ ' -  p3 
tained in both 293 cells (Figure 6A) and SK-N-SH cells 
(Figure 6D) after overnight labeling and were also seen 
after a 2 hr pulse labeling in the 293 cells (data not shown). 
When cell extracts were precipitated with the C-terminal 
antibody C7, all transfected cells were found to overpro- 
duce membrane-bound, full-length 13APP (data not shown) 
and a 10 kDa C-terminal fragment that remains mem- 
brane-bound after release of APP, into the medium (293 
cells, Figure 6C; SK-N-SH cells, Figure 6F). An additional 
12 kDa C-term inal fragment is observed in S K-N-SH neuro- 
blastoma cells transfected with wild-type 13APP69~ (Figure 
6F). This band becomes much more pronounced in Swed- 
ish SK-N-SH transfectants, is barely detectable in the 
M596V transfectants, and is replaced by a shorter - 11.5 
kDa band in the D597A transfectant (Figure 6F). A C-ter- 
minal fragment of similar size has been previously ob- 
served to be increased in M17 human neuroblastoma cells 
transfected with 13APP carrying the Swedish mutation and 
was thus hypothesized to be an immediate precursor f
AI3 that has not yet undergone 7-secretase cleavage (Cai 
et al., 1993). Indeed, both the amounts and the size of 
this fragment correlate with the amounts and the size of 
AI3 in our various SK-N-SH transfectants (compare Figures 
6D and 6F). Radiosequencing of the Swedish 12 kDa pro- 
tein confirms that it indeed starts at Asp-1 (major peak of 
radioactive Phe in cycle 4; Figure 6G). It seems highly 
likely that the substitutions examined primarily influence 
the N-terminal cleavage of AI3 and not other I?,APP proteo- 
lytic processing pathways, because we did not observe 
any substantial differences in cellular full-length ~APP 
(data not shown) or decreases in total APPs (Figures 6B 
and 6E). 
We next set out to test an extensive panel of N-terminal 
substitutions for their effect on AI3 production in 293 cells. 
For each substitution, the R1280 immunoprecipitates of 
AI3 and p3 are shown in Figure 7. The relative ratios of 
A~ to full-length I~APP, determined by phosphorimaging 
and set as 1.0 for the wild type in each panel, are indicated 
(Figure 7). All of the substitution mutants produced full- 
length J3APP and APPs (data not shown). Likewise, p3 was 
secreted by all of the mutants analyzed, although in vary- 
ing amounts. In contrast, AI3 production was markedly af- 
fected by most substitutions. Changes at V594 strongly 
decreased AI3 production, whereas no clear effect was 
observed for two substitutions for K595. Several substitu- 
tions at the pl position M596 were analyzed. The pre- 
viously described M596L substitution of the Swedish mu- 
tation (Citron et al., 1992) led to an increase in AlL Of all the 
other substitutions, only the hydrophobic, bulky residues F 
and Y did not lead to a strong decrease in AI3 (Figure 7B). 
The AI3 4 kDa species was virtually eliminated by all the 
D597 substitutions. Only D597E still showed the original 
AI3 band (Figure 7C). However, in all these D597 substitu- 
tions, intermediate bands of - 3.8 kDa appeared that were 
not observed from wild-type constructs (Figure 7C), as 
shown above for D597A (Figure 6D). Substitutions of A598 
also had a marked inhibitory effect on AI3 production (Fig- 
ure 7D). In summary, almost all of the single amino acid 
substitutions at and immediately around the N-terminal 
cleavage site markedly decreased AI3 production. 
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Discussion 
In this work, we have used human 293 cells to establish 
the substrate requirements of proteases that cleave I~APP 
at the N-terminus of AlL We show that three 13APP mutants 
producing strong, but distinct, effects on AI3 production 
in this cellular system give essentially identical results in 
human SK-N-SHneuroblastoma cells. These data sug- 
gest that mutations around the Met-Asp cleavage site may 
lead to similar changes in AI3 production in other neural 
and nonneural cell types. Our findings demonstrate that 
the region defined by residues 590-600 (13APPsg~ number- 
ing) is sufficient for recognition and efficient cleavage of 
the precursor by the AI~ N-terminal protease(s). When the 
cleavage site is moved 5 amino acids closer to the mem- 
brane, there is no effect on cleavage, as demonstrated by 
N-terminal sequencing of the product. This result suggests 
that the protease(s), designated 13-secretase(s), recog- 
nizes the primary structure around the cleavage site inde- 
pendently of its distance from the membrane, a property 
which is the opposite of that postulated for (~-secretase 
(Sisodia, 1992). The fact that I~-secretases do not require a 
fixed distance to the membrane in order to cleave suggests 
that the proteases themselves are not membrane an- 
chored. However, they can only act on membrane-bound 
13APP molecules in intact cells, because otherwise the 
STOP40 and STOP40sw forms of 13APP would give rise 
to AI3, as do the STOP51 and STOP51sw constructs, 
which also lack the cytoplasmic domain but contain most 
of the transmembrane domain. The fact that only mem- 
brane-bound 15APP is N-terminally cleaved in vivo implies 
that AI3 is very unlikely to be produced extracellularly from 
larger secreted N- or C-terminal fragments of full-length 
~APP, at least not by the same proteases that produce 
AI3 in intact cells. 
Two lines of indirect evidence suggest that more than 
one protease can generate the N-terminus of AI~: first, the 
wild-type 13APP molecule can be processed into Al3-related 
peptides starting at different positions in a cell type-de- 
pendent manner; second, the N-terminal sequence heter- 
ogeneity of AI3 peptides produced in 293 cells suggests 
the action of more than one enzyme, particularly in view 
of our finding here that the Met-Asp cleaving enzyme is 
highly sequence specific. The results of substitutions at 
the pl position, in which only the large hydrophobic resi- 
dues Met, Leu, Phe, and Tyr allowed cleavage, are consis- 
tent with the primary cleavage at Asp-1 being produced 
by a chymotryptic-like proteinase. Based on our AI3 se- 
quencing data, this enzyme would be the only one capable 
of creating the AI~ N-terminus in fibroblasts, would be the 
predominant enzyme in 293 cells, and would be virtually 
absent from the normal AI3 production pathway in Madin- 
Darby canine kidney cells (in which AI3 begins primarily at 
Arg-5). 13APP substrates with mutations around the regular 
N-terminal cleavage site could then be recognized by other 
proteases with different specificities. This would explain 
the 3.8 kDa peptides that arise after virtually any substi- 
tution at D597. The situation is complicated further by 
the fact that not all enzymes capable of cleaving the 
N-terminus of AI5 need necessarily be located in the same 
subcellular compartment. It has recently been demon- 
strated that one site of AI3 generation is within an early 
endosome following reinternalization f 13APP from the cell 
surface (Koo and Squazzo, 1994). However, 13APP mole- 
cules such as STOP51, in which the reinternalization sig- 
nal is deleted, still produce AI3, albeit in reduced amounts 
and with increased levels of AI],-related peptides starting 
at positions other than Asp-l. 
Most of the single amino acid substitutions we tested 
substantially decreased or eliminated AI3 production. We 
believe this result is due to reduced cleavage at the AI3 
N-terminus rather than to decreased stability of the peptide 
or destruction of an epitope essential for the immunopre- 
cipitation, because substitutions at V594 and M596 in front 
of the cleavage site would not influence antibody recogni- 
tion or stability of a peptide starting at D597. Furthermore, 
the loss of the 4 kDa peptide in D597A was also observed 
in a short-pulse experiment, arguing against AI~ destabili- 
zation by substitution as a cause for its reduction in the 
D597 mutants. The fact that R1280 precipitates p3 shows 
that it does not recognize solely epitopes at the N-terminus 
of AlL This makes it unlikely that single amino acid substi- 
tutions at the AI3 N-terminus would completely block 
R1280 binding and thereby account for the disappearance 
of the 4 kDa band. 
Our data underscore the previous conclusion that p3 
arises from a different processing pathway than AI3 (Haass 
et al., 1993). The fact that only the Swedish mutation, with 
its M596L substitution, clearly increases AI3 production is 
consistent with the assumption that the Leu-Asp bond is 
a much better substrate than the wild-type Met-Asp bond 
for an Asp-1 cutting protease that cleaves I~APP during its 
transport o the cell surface. This cleavage would happen 
prior to the reinternalization that appears to be necessary 
for the principal Asp-1 cleavage event in the wild-type sub- 
strate. Such a model would explain why the cleavage pat- 
tern of Swedish 13APP is not affected by C-terminal trunca- 
tions like STOP51sw that delete the internalization 
signals. Because none of the other mutants we examined 
besides M596L led to such a strong increase in AI3 produc- 
tion, we speculate that any other polymorphisms around 
the cleavage site would also be phenotypically silent, mak- 
ing it unlikely that additional FAD mutations which cause 
increased AI3 production will be mapped to the N-terminus 
of AlL 
The present investigation describes several properties 
of the 13-secretase nzymes that produce AI5 in living hu- 
man cells and also allows two general conclusions about 
the C-terminal y-secretase cleavage. First, the correlation 
of the amount of the 12 kDa C-terminal 15APP fragment 
starting at Asp-1 with the amount of AI3, and the correlation 
of the amount of the respective 11.5 kDa fragment pro- 
duced by D597A with the amount of the shortened AI3-type 
peptide starting at Phe-4 in SK-N-SH cells, confirm the 
previous suggestion of Cai et al. (1993) that the 12 kDa 
fragment can serve as the immediate precursor of AI3 and 
indicate that 13-secretase cleavage occurs before y-secre- 
tase cleavage. The 12 kDa molecule has not been ob- 
served, however, in transfected 293 cells (Figure 6C) (Cit- 
ron et al., 1992) or in primary skin fibroblasts from patients 
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carrying the Swedish FAD mutation (Citron et al., 1994), 
suggesting that there are cell type differences in the rate 
at which the 12 kDa molecule undergoes y-secretase 
cleavage. Second, because A~ is still produced from con- 
structs like STOP51sw, "y-secretase does not require the 
cytoplasmic domain of J3APP to recognize and cleave the 
C-terminus of AJ~. 
Finally, our description of the substrate specificity of 
the protease has important practical consequences. For 
example, our data suggest that ~APP recombinant deriva- 
tives or synthetic peptides used to identify and character- 
ize this protease must at least include Val-594 to Ala-598. 
Furthermore, one can now design control substrates with 
substitutions like M596V, which should not be cleaved well 
by the candidate protease. However, as we have shown 
here, only membrane-bound 13APP undergoes N-terminal 
cleavage in vivo. If this need for membrane anchoring re- 
flects a requirement of the protease rather than a require- 
ment for substrate compartmentalization and targeting, 
then I~APP derivatives and synthetic peptides that are not 
membrane bound should not be recognized by the prote- 
ase for which they are designed. Therefore, the use of 
synthetic peptides or recombir~ant fragments in solution 
to screen for ~-secretase might well lead to the isolation 
of irrelevant enzymes. These various considerations em- 
phasize the importance of acquiring in vivo data in intact 
human cells when searching for physiologically relevant 
proteases. 
Experimental Procedures 
Transfection, Metabolic Labeling, Preparation of 
Total Cell Lysates, Immunoprecipitation, and 
Protein Radiosequencing 
Details of these methods have been described previously (Haass et 
al., 1992b). Briefly, subconfluent 10 cm dishes of human embryonic 
kidney 293 cells or SK-N-SH human neuroblastoma cells were tran- 
siently transfected with 20 Hg of supercoiled plasmid DNA using Lipo- 
fectin (GIBCO/BRL) as described by the manufacturer. About 48 hr 
after transfection, cells were metabolically abeled with [3SS]methionine 
overnight. Immunoprecipitations were performed as described (Haass 
et al. 1992b). Immunoprecipitated APP, was separated on a 10% 
SDS-polyacrylam ide gel, whereas precipitates of A~ and p3 from me- 
dia and precipitates of cell extracts were separated on 10%-20% Tris- 
Tricine gels. Autofluorography was car-led out as described (Haass et 
al., 1992b). Bands were quantitated by phosphorimaging, Radioactive 
sequencing of the 4 kDa (A~,) end 3 kDa (p3) peptides was performed 
after R1280 immunoprecipitation f transiently transfected cells meta- 
bolically labeled with L-[2,3,4,5,6-3H]phenylalanine as described 
(Haass et al., 1992b). 
Antibodies Used for Immunoprecipi~ation 
The polyclonal antibody C7 (Podlisny et al., 1991) is directed against 
the last 20 amino acids of the cytoplasmic tail of ~APP. This antibody 
immunoprecipitates N'- and N'+O'-glycosylated full-length ~APP and 
the 10 kDa fragment. The affinity-purified polyclonal antibody B5 (OI- 
tersdorf et al., 1990) was raised to a recombinantly expressed protein 
of ~APP~-~g2 and immunoprecipitates APP, and N'- and N'+O'- 
glycosylated full-length ~APP. The pclyclonal antibody R1280 (Ta- 
maoka et al., 1992) was raised to synthetic A~-4o. This antibody immu- 
noprecipitates AI3, p3, and small, variab!e amounts of APP. from media 
of tissue culture cells (Haass et al., 1992b). The polyclonal antibody 
1963 (Haass et al., 1992b) was raised to synthetic A1~2~_37. 
Plasmid Constructions 
All constructs used in this paper are derivatives of pCMV695, a plasmid 
carrying f, APP69~ cDNA under control of the CMV promoter (Selkoe 
et al., 1988). Constructs containing single amino acid substitutions 
were designed by replacing the 26 bp BglII-EcoRI fragment of f, APP69s 
with annealed oligonucleotides inwhich codon 594,595, 596, 597, or 
598 was changed to encode the mutant amino acid: GTG was changed 
to TGG in V594W and deleted in V594&; AAG was changed to AAT 
in K595N and to GAG in K595E; ATG was deleted in M596A and 
changed to CTG in M596L, to TAT in M596Y, to GTG in M596V, to 
GCC in M596A, to AAG in M596K, to GAG in M596E, to ATC in M5961, 
and to TTC in M596F; GAT was deleted in D597A and changed to 
AAA in D597K, to GGA in D597G, to ATC in D5971, to AAC in D597N, 
and to GAA in D597E; GCA was deleted in A598A and changed to 
GAG in A598E and to AAG in A598K. The plasmids XB and XBsw 
were engineered by deleting the XhoI-Bglll fragment from pCMV695 
and pCMV695 KM-NL (Citron et al., 1992), respectively, and replacing 
it with the annealed oligonucleotides TCGAGACACCTGGGGA and 
GATCTCCCCAGGTGTC, The plasmids z~5-9, 49-12, Stop40, and 
Stop51 were generated by site-directed mutagenesis (Kunkel, 1985) 
of ~APPsg~ cDNA using the oligonucleotides: CCAAi I I I iGATGAT- 
GAAC'I-IC ATAGAATTCGTAATCATGGTCAT, GAACACCAAI I I I I- 
GATGTGAGTCATGTCGGAATTCGTAATC, GATCACTGTCGCTTA- 
GACAACACCGCC, and CTGTTI'CTTCTTCTAGATAACCAAGGTGA- 
TGAC, respectively. The constructs STOP51sw and STOP4Osw were 
engineered by replacing the wild-type EcoRI-Spel fragment of the 
Swedish mutant construct ~APP~s KM-NL (Citron et al., 1992) with 
the EcoRI-Spel fragment from STOP51 and STOP40, respectively. 
Except for XB, all mutations were verified by DNA sequencing. 
Preparation of Isolated Membranes 
A postnuclear supernatant was prepared as described previously 
(Haass et al., 1992a) and pelleted to remove cytoplasmic proteins by 
a high speed spin for 1 hr at 50,000 rpm (233,000 g) at 4°C in a 
Beckman 55Ti rotor. Isolated membranes were carbonate extracted 
as described (Fujiki et al,, 1982). The homogenate was pelleted as 
described above. For each sample, 15 pg of total protein were loaded 
on a 10% SDS-polyacrylamide gel. Transfer and immunoblotting were 
performed as described (Haass et al., 1992a). 
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